Research at Stanford University has determined that skin scarring is mostly the work of structural cells called fibroblasts. When these cells are inhibited in mice, scars did not form, nor was there a compromise in structural integrity of the skin. A currently approved drug for treating type II diabetes has been shown to inhibit a marker on the fibroblast surface, thus preventing scars from forming. Human trials will elucidate whether the drug can be useful for those undergoing major surgeries and radiation.


TIME Magazine
See article in Science here